Press release
Glioma Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024
Request a sample and discover the recent advances in Glioma @ Glioma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Glioma Pipeline Report
* In September 2024:- Day One Biopharmaceuticals Inc- This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
* In September 2024:- Chimerix- This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
* DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.
* The leading Glioma Companies working in the market include BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen , and others.
* Promising Glioma Therapies in the various stages of development include DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103 , and others.
Learn more about Glioma in clinical trials @ Glioma Treatment Drugs [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Glioma Disease Emerging Drugs
* ONC 201: Chimerix
* Marizomib: Bristol-Myers Squibb
* MDNA55: Medicenna Therapeutics, Inc.
* CAN-3110: Candel Therapeutics
Glioma Therapeutics Assessment
There are approx. 180+ Glioma companies which are developing the Glioma therapies. The Glioma Companies which have their Glioma Disease drug candidates in the most advanced stage, i.e. Phase III include, Chimerix.
DelveInsight's Glioma Pipeline Report covers around 200+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Discover more about Glioma in development @ Glioma Clinical Trials [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Glioma Companies
BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.
The Glioma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Glioma Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
To know more about Glioma, visit @ Glioma Therapeutics Segmentation [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Glioma Pipeline Report
* Coverage- Global
* Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Glioma Companies- BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.
* Glioma Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
For further information on the Glioma Pipeline Therapeutics, reach out @ Glioma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Glioma Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Glioma Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* ONC 201: Chimerix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Safusidenib: AnHeart Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CAN-3110: Candel Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Glioma Disease Key Companies
* Glioma Disease Key Products
* Glioma Disease- Unmet Needs
* Glioma Disease- Market Drivers and Barriers
* Glioma Disease- Future Perspectives and Conclusion
* Glioma Disease Analyst Views
* Glioma Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-treatment-drugs-clinical-trials-pipeline-insights-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024 here
News-ID: 3669823 • Views: …
More Releases from ABNewswire
North America Healthcare Simulation Market to Reach USD 2.99 Billion by 2030, Gr …
North America Healthcare Simulation Market by Product [Patient Simulator, Task Trainer, Surgical (Lapro, Ortho, Gynae, Cardio), Ultrasound, Training], Technology [3D Printing, Virtual Patient, Procedural Rehearsal], End User [Academic]-Forecast to 2030
The North America Healthcare Simulation Market is projected to grow from USD 1.48 billion in 2025 to USD 2.99 billion by 2030, registering a strong CAGR of 15.1% during the forecast period. Market expansion is fueled by the rapid adoption of…
Zero Trust Security Market Leading Companies, Growth Factors, Healthy CAGR, Oppo …
Zero Trust Security Market by (IAM, Microsegmentation, ZTNA, ZTDA, SIEM, Policy Management), Application (Access Control, API Security, User Behaviour), Single-factor, Multi-factor, Security (Network-Application-Cloud-Data-Endpoint-IoT) - Forecast to 2029.
The global zero trust security market [https://www.marketsandmarkets.com/Market-Reports/zero-trust-security-market-2782835.html?utm_campaign=zerotrustsecuritymarket&utm_source=abnewswire.com&utm_medium=referral] is expected to expand at a compound annual growth rate (CAGR) of 16.6% from USD 36.5 billion in 2024 to USD 78.7 billion by 2029. Because cyber threats are becoming more complicated and people are depending more…
Grignard Reagents Market 2026 Emerging Demands, Share, Trends, Futuristic Opport …
The Grignard Reagents market is poised for steady growth, driven by rising demand in pharmaceuticals, agrochemicals, and specialty chemicals. Expanding applications in complex organic synthesis and increasing R&D investments are key trends shaping the market. Additionally, advancements in handling and storage technologies are enhancing safety and scalability, supporting broader industrial adoption.
The Grignard reagents market is projected to grow from USD 5.07 billion in 2025 to USD 6.67 billion by 2030,…
Steel Wire Rope Market Growth: Analyzing Demand, Scope, Size, Share, and Forecas …
The steel wire rope market is witnessing steady growth, driven by rising demand from construction, mining, marine, oil & gas, and infrastructure sectors. Increasing investments in urban development and lifting applications, along with advancements in high-strength, corrosion-resistant ropes, are shaping market trends. Asia-Pacific remains dominant, while sustainability and safety standards continue to influence product innovation.
The steel wire rope market is projected to reach USD 13.88 billion by 2030 from USD…
More Releases for Glioma
Glioma Market Growth Opportunities 2025-2034
Market Overview
The Glioma Market is witnessing steady growth as new therapeutic approaches continue to emerge for one of the most aggressive and complex forms of brain tumors. Gliomas originate in glial cells and represent the majority of malignant brain cancers. The increasing global incidence of glioblastoma and other high-grade gliomas, combined with rising awareness, improved diagnostic capability, and expanded research in precision oncology, is driving market demand. Novel immunotherapies, targeted…
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
